Traditional methods for quantifying the activity of VEGF are based on the ability of anti-VEGF antibodies to inhibit the proliferation of cells expressing VEGFR receptors, following treatment with VEGF. These assays can take days, suffer from high variability and are difficult to validate.
In a recent paper, Lallemand and colleagues have used iLite® VEGF reporter-gene assays and ADCC assays from Svar Life Science to analyze samples from patients with ovarian cancer and glioblastoma that had been treated with bevacizumab.
They found that it is possible to quantify the direct VEGF neutralizing activity of bevacizumab, as well as the host mediated ADCC activity in the samples. In addition, they found clear differences between samples from individual patients.
Read the Paper (open access)